The FDA granted rare pediatric disease designation to VG901 for the treatment of retinitis pigmentosa caused by mutations in the CNGA1 gene, according to a press release from ViGeneron.
The designation allows the company to receive a priority review voucher upon marketing approval of VG901 that could be used to reduce the review period for any of ViGeneron’s drug candidates.
In addition, ViGeneron announced that an independent data safety monitoring board has unanimously approved dose escalation in an ongoing phase 1b clinical trial investigating the safety and preliminary efficacy of